Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Open-label Study of Lifileucel (Tumor-infiltrating Lymphocytes [TIL]) in Participants With Previously Treated Advanced Endometrial Cancer.

NCT06481592 is registered in ClinicalTrials.gov with Iovance Biotherapeutics, Inc. as lead sponsor.

NCT NCT06481592
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06481592 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Open-label Study of Lifileucel (Tumor-infiltrating Lymphocytes [TIL]) in Participants With Previously Treated Advanced Endometrial Cancer.
Lead sponsor
Iovance Biotherapeutics, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
October 29, 2024
Completion date
November 30, 2029
Enrollment
60 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer